Alnsasra Hilmi, Ben-Avraham Binyamin, Gottlieb Shmuel, Ben-Avraham Merav, Kronowski Ran, Iakobishvili Zaza, Goldenberg Ilan, Strasberg Boris, Haim Moti
Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Rabin Medical Center, Petah Tikva, Israel.
J Electrocardiol. 2018 May-Jun;51(3):386-391. doi: 10.1016/j.jelectrocard.2018.03.003. Epub 2018 Mar 7.
High-grade atrioventricular block (HAVB) is a frequent complication of acute myocardial infarction (AMI) and is associated with increased morbidity and mortality. We aimed to evaluate the incidence, predictors, and prognostic significance of HAVB in a contemporary cohort of patients with AMI, in the recent era of early reperfusion. Patients with acute coronary syndromes (n=11,487) during the years 2000-2010 were included. Patients were divided into two groups: with HAVB (n=308, 2.7%) and without HAVB (n=11,179, 97.3%). The incidence of HAVB decreased from 4.2% in 2000 to 2.1% in 2010 (p for trend<0.01). Patients with HAVB were more likely to develop in-hospital complications. Independent predictors of developing HAVB were older age, ST-elevation myocardial infarction (STEMI), smoking and Killip class≥2 on admission. 30-day and 1-year mortality rates were significantly higher in the HAVB as compared to the non-HAVB group (24% vs. 4.9%, p<0.01, 33.5% vs. 10%, p<0.01, respectively). Multivariable logistic regression analysis revealed that, HAVB was associated with increased 30-day (OR - 3.97; 95% CI - 1.96-8.04) and 1-year mortality risk (HR - 2.02; 95% CI - 1.3-3.1). Similar estimates were obtained for STEMI and non-STEMI (NSTEMI). In conclusion, although the incidence of HAVB decreased over the last decade, the associated morbidity and mortality are still high in these patients despite early reperfusion therapy.
高度房室传导阻滞(HAVB)是急性心肌梗死(AMI)的常见并发症,与发病率和死亡率增加相关。我们旨在评估在早期再灌注的当代AMI患者队列中HAVB的发生率、预测因素及预后意义。纳入了2000年至2010年期间患有急性冠状动脉综合征(n = 11487)的患者。患者分为两组:有HAVB组(n = 308,2.7%)和无HAVB组(n = 11179,97.3%)。HAVB的发生率从2000年的4.2%降至2010年的2.1%(趋势p<0.01)。有HAVB的患者更易发生院内并发症。发生HAVB的独立预测因素为年龄较大、ST段抬高型心肌梗死(STEMI)、吸烟以及入院时Killip分级≥2级。与无HAVB组相比,HAVB组的30天和1年死亡率显著更高(分别为24%对4.9%,p<0.01;33.5%对10%,p<0.01)。多变量逻辑回归分析显示,HAVB与30天死亡风险增加相关(比值比 - 3.97;95%置信区间 - 1.96 - 8.04)以及1年死亡风险增加相关(风险比 - 2.02;95%置信区间 - 1.3 - 3.1)。STEMI和非STEMI(NSTEMI)患者也得到了类似的估计值。总之,尽管在过去十年中HAVB的发生率有所下降,但尽管进行了早期再灌注治疗,这些患者的相关发病率和死亡率仍然很高。